Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galatea: TP-04 in Papulopustular Rosacea
NCT05838170Phase 2Completed
- Sponsor
- Tarsus Pharmaceuticals, Inc.
- Start
- Mar 2023
- Primary completion
- Nov 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lotilaner in papulopustular rosacea, sponsored by Tarsus Pharmaceuticals, Inc.. Started Mar 2023; status: completed.
02
Drugs
lotilaner
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT05838170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05838170.